Bevacizumab-pemetrexed/cisplatin combination therapy (BEV-PEM/CIS) is a first line therapeutic for non-small cell lung cancer (NSCLC). (more…)
Full manuscript available here.
Presented as a Poster at the BIVI-NIH National Veterinary Scholar Symposium (Aug 2-5, 2018) and the Iowa State University’s CVM Summer Scholar Research Day (Aug 10, 2018)
Full article available here.